N@N

Exact Sciences to Host First-Quarter 2011 Results Conference Call

^{Published on 2011-04-26 08:40:57 - Market Wire}
 

MADISON, Wis.--([ BUSINESS WIRE ])--Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a conference call and webcast on May 3, 2011, at 10 a.m. ET, to discuss the companya™s first-quarter financial results.

First-Quarter 2011 Conference Call Details

An archive of the first-quarter 2011 webcast will be available at [ www.exactsciences.com ]. A replay of the conference call is available by calling 800-642-1687 domestically or 706-645-9291 internationally. The access code for the replay is 63138476. The webcast, conference call and replay are open to all interested parties.

About Exact Sciences Corp.

Exact Sciences Corp. is a molecular diagnostics company focused on colorectal cancer. The company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, please visit the companya™s website at [ www.exactsciences.com ].

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the asafe harbora created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as abelieve,a aexpect,a amay,a awill,a ashould,a acould,a aseek,a aintend,a aplan,a aestimate,a aanticipatea or other comparable terms. Forward-looking statements in thispresentationmay address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, anticipated results of our pivotal clinical trial, expected license fee revenues, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Managementa™s Discussion and Analysis of Financial Condition and Results of Operations sectionsof ourmost recently filedAnnual Report on Form 10-Kand oursubsequently filedQuarterly Reports of Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.